Levemir / other basal insulins (class totals high)

Basal insulins are long-acting insulin analogues used to help manage blood glucose levels over an extended period (typically ~24 hours). They are a cornerstone of insulin therapy for patients with type 1 diabetes (in combination with rapid-acting insulins for meals) and for many patients with type 2 diabetes requiring insulin therapy.

Active Ingredient (Example — Levemir):

• Insulin Detemir (100 U/mL) — a soluble insulin analogue designed to be slowly released into the bloodstream after subcutaneous injection to mimic natural basal insulin secretion.

Mechanism of Action:
Basal insulin analogues bind to insulin receptors and facilitate cellular uptake of glucose while suppressing hepatic glucose production, contributing to stable baseline glycemic control throughout the day and overnight.

Indications:

• Type 1 Diabetes Mellitus: used as part of a basal-bolus regimen to maintain baseline insulin.

• Type 2 Diabetes Mellitus: when oral therapies and/or other injec­tables are insufficient to achieve glycemic targets.

Typical Administration:

• Route: Subcutaneous injection

• Dosing: Individualized by a healthcare provider; may be administered once per day (for many basal insulins) or twice per day for some detemir regimens depending on glycemic response and clinical guidance.

Benefits:

• Helps maintain baseline glucose control between meals and overnight

• Reduces risk of wide glucose fluctuations

• Can be combined with rapid-acting insulins for optimal daily glucose coverage

Safety & Precautions:

• Hypoglycemia Risk: The most serious risk; monitor blood glucose regularly and adjust dose as needed.

• Weight Changes: Some patients may experience changes in weight as glycemic control improves.

• Injection Site Reactions: Possible erythema or irritation.

• Prescription Only: Insulins require a valid clinician prescription and personalized dose titration.

Common Side Effects:

• Hypoglycemia (low blood glucose)

• Injection site redness or itching

• Edema (fluid retention), particularly with initiation or dose changes

Storage:

• Store unopened insulin in the refrigerator (2°C–8°C).

• After first use, many pen or vial products may be kept at room temperature per manufacturer instructions, typically up to 28 days.